HBV
Hepatitis B virus
HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.
All Product Categories
-
HBV Related Products (384)
Related Products (384)
-
Antibodies (2)
-
HBV-IN-14
0 ImagesCat. No.: HY-144045CAS No.: 2712529-19-4HBV-IN-14 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-14 is a pyridinopyrimidinones compound. HBV-IN-14 has the potential for the research of HBV infection (extracted from patent WO2021190502A1, compound 5).
-
(-)-Carbovir
0 ImagesSynonyms: (-)-NSC 614846(-)-Carbovir is an active compound.
-
Bentysrepinine
0 ImagesCat. No.: HY-111073CAS No.: 934264-38-7Synonyms: Y101Bentysrepinine (Y101) is an orally active HBV inhibitor with anti-hepatitis B virus infection activity. Bentysrepinine exhibits favorable pharmacokinetic characteristics, with absolute bioavailability of 44.9%, 43.1%, and 19.2% in rats, dogs, and monkeys, respectively, and it does not accumulate in monkeys after 90 days of oral administration. Bentysrepinine is under research in the antiviral and hepatitis fields.
-
HBV-IN-12
0 ImagesCat. No.: HY-145059CAS No.: 2724229-06-3HBV-IN-12 is a potent hepatitis B surface antigen (HBsAg) inhibitor (0.001 μM< EC50 ≤0.05 μM). HBV-IN-12 shows anti-HBV DNA activity (0.001 μM＜EC50 ≤0.02 μM). From patent WO2021204252A1, compound 15.
-
HBV-IN-24
0 ImagesCat. No.: HY-147863CAS No.: 3034440-12-2
-
HBV-IN-22
0 ImagesCat. No.: HY-146394CAS No.: 2338573-94-5
-
D-CAM-14
0 ImagesCat. No.: HY-179265D-CAM-14 is a potent HBV capsid assembly modulator with potent anti-HBV activity (EC50 = 0.1 nM, EC90 = 9 nM in HepAD38 cells). D-CAM-14 suppresses HBeAg, and HBcAg in HBV-infected HepG2-NTCP cells, with EC50 values of 98 and 67 nM, respectively. D-CAM-14 has distinct impacts on capsid radii and the morphology of preassembled capsids. D-CAM-14 can be used for HBV infection disease research.
-
Taurolithocholic acid-d4-1 sodium
0 ImagesCat. No.: HY-113308AS2Taurolithocholic acid-d4-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis.
-
Schisanwilsonin K
0 ImagesCat. No.: HY-N19941CAS No.: 1610530-95-4
-
Periglaucine B
0 ImagesCat. No.: HY-N3093CAS No.: 1025023-05-5Synonyms: (+)-Periglaucine BPeriglaucine B ((+)-Periglaucine B) is an alkaloid and an HBsAg inhibitor. Periglaucine B can be isolated from Pericampylus glaucus. Periglaucine B inhibits the secretion of hepatitis B virus (HBV) surface antigen (HBsAg) in Hep G2.2.15 cells with an IC50 of 0.47 mM.
-
Lamivudine-13C,15N2,d2
0 ImagesCat. No.: HY-B0250S1Synonyms: BCH-189-13C,15N2,d2Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase.
-
HBV-IN-6
0 ImagesCat. No.: HY-145049CAS No.: 2724224-47-7HBV-IN-6 is a potent HBV inhibitor with an EC50 of 44 nM (WO2021213445A1, compound 3).
-
HBV Seq2 aa:208-216
0 ImagesCat. No.: HY-P4045CAS No.: 160214-63-1HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus.
-
HBV-IN-38
0 ImagesCat. No.: HY-156702CAS No.: 1834483-86-1HBV-IN-38 (Example 193) is an HBV DNA inhibitor (EC50≤100nM). HBV-IN-38 can be used to study viral infections.
-
HBV/HDV-IN-2
0 ImagesCat. No.: HY-161605CAS No.: 3034161-76-4HBV/HDV-IN-2 (Compd 143) is a HBV, HDV and PD-1/PD-L1 inhibitor, with an EC50 of 35 nM for T cell activation.
-
Erythrocentaurin
0 ImagesCat. No.: HY-N3861CAS No.: 50276-98-7Erythrocentaurin, a natural compound, is a new class of hepatitis B virus inhibitor.
